Pressurized Metered Dose Inhaler Technology: Manufacturing

Ernest Vallorz, Poonam Sheth, Paul B Myrdal

Research output: Contribution to journalReview article

Abstract

While first introduced in the 1950s, pressurized metered dose inhalers (pMDIs) remain as a first line treatment of pulmonary conditions. With expanding applications of pMDIs beyond asthma and chronic obstructive pulmonary disease (COPD), the development of therapies utilizing the pMDI platform will undoubtedly continue. Recent guidances and the introduction of quality by design initiatives further emphasize the requirement of formulators to understand the relationships between product attributes and production strategies and their impact on product performance. This review summarizes common manufacturing processes of pMDIs across multiple stages of the development cycle, from academia to commercial production, and provides insight as to the benefits and limitations of each process in regard to formulation type.

Original languageEnglish (US)
Article number177
JournalAAPS PharmSciTech
Volume20
Issue number5
DOIs
StatePublished - Jul 1 2019

Fingerprint

Metered Dose Inhalers
manufacturing
Technology
dosage
asthma
respiratory tract diseases
Chronic Obstructive Pulmonary Disease
Asthma
lungs
Lung
therapeutics
Therapeutics

Keywords

  • cold filling
  • critical quality attribute (CQA)
  • manufacturing
  • pressure filling
  • pressurized metered dose inhaler (pMDI)

ASJC Scopus subject areas

  • Agronomy and Crop Science
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Pressurized Metered Dose Inhaler Technology : Manufacturing. / Vallorz, Ernest; Sheth, Poonam; Myrdal, Paul B.

In: AAPS PharmSciTech, Vol. 20, No. 5, 177, 01.07.2019.

Research output: Contribution to journalReview article

Vallorz, Ernest ; Sheth, Poonam ; Myrdal, Paul B. / Pressurized Metered Dose Inhaler Technology : Manufacturing. In: AAPS PharmSciTech. 2019 ; Vol. 20, No. 5.
@article{f57360be6c21470bb802e4124d6a6563,
title = "Pressurized Metered Dose Inhaler Technology: Manufacturing",
abstract = "While first introduced in the 1950s, pressurized metered dose inhalers (pMDIs) remain as a first line treatment of pulmonary conditions. With expanding applications of pMDIs beyond asthma and chronic obstructive pulmonary disease (COPD), the development of therapies utilizing the pMDI platform will undoubtedly continue. Recent guidances and the introduction of quality by design initiatives further emphasize the requirement of formulators to understand the relationships between product attributes and production strategies and their impact on product performance. This review summarizes common manufacturing processes of pMDIs across multiple stages of the development cycle, from academia to commercial production, and provides insight as to the benefits and limitations of each process in regard to formulation type.",
keywords = "cold filling, critical quality attribute (CQA), manufacturing, pressure filling, pressurized metered dose inhaler (pMDI)",
author = "Ernest Vallorz and Poonam Sheth and Myrdal, {Paul B}",
year = "2019",
month = "7",
day = "1",
doi = "10.1208/s12249-019-1389-9",
language = "English (US)",
volume = "20",
journal = "AAPS PharmSciTech",
issn = "1530-9932",
publisher = "American Association of Pharmaceutical Scientists",
number = "5",

}

TY - JOUR

T1 - Pressurized Metered Dose Inhaler Technology

T2 - Manufacturing

AU - Vallorz, Ernest

AU - Sheth, Poonam

AU - Myrdal, Paul B

PY - 2019/7/1

Y1 - 2019/7/1

N2 - While first introduced in the 1950s, pressurized metered dose inhalers (pMDIs) remain as a first line treatment of pulmonary conditions. With expanding applications of pMDIs beyond asthma and chronic obstructive pulmonary disease (COPD), the development of therapies utilizing the pMDI platform will undoubtedly continue. Recent guidances and the introduction of quality by design initiatives further emphasize the requirement of formulators to understand the relationships between product attributes and production strategies and their impact on product performance. This review summarizes common manufacturing processes of pMDIs across multiple stages of the development cycle, from academia to commercial production, and provides insight as to the benefits and limitations of each process in regard to formulation type.

AB - While first introduced in the 1950s, pressurized metered dose inhalers (pMDIs) remain as a first line treatment of pulmonary conditions. With expanding applications of pMDIs beyond asthma and chronic obstructive pulmonary disease (COPD), the development of therapies utilizing the pMDI platform will undoubtedly continue. Recent guidances and the introduction of quality by design initiatives further emphasize the requirement of formulators to understand the relationships between product attributes and production strategies and their impact on product performance. This review summarizes common manufacturing processes of pMDIs across multiple stages of the development cycle, from academia to commercial production, and provides insight as to the benefits and limitations of each process in regard to formulation type.

KW - cold filling

KW - critical quality attribute (CQA)

KW - manufacturing

KW - pressure filling

KW - pressurized metered dose inhaler (pMDI)

UR - http://www.scopus.com/inward/record.url?scp=85065127219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065127219&partnerID=8YFLogxK

U2 - 10.1208/s12249-019-1389-9

DO - 10.1208/s12249-019-1389-9

M3 - Review article

C2 - 31037395

AN - SCOPUS:85065127219

VL - 20

JO - AAPS PharmSciTech

JF - AAPS PharmSciTech

SN - 1530-9932

IS - 5

M1 - 177

ER -